Therefore, we expect that drugs targeting the K31 sumoylation pathway will inhibit TH17-mediated pathological immunity without interfering with thymocyte survival or cell cycle regulation, which could induce lymphoma in patients. The gene discussed is KRT31; the disease is lymphoma.